Extended sensitivity of biotherapeutic pharmacokinetic (PK) & biomarker immunoassays.

In this webinar, three speakers will present the application of microfluidic, nanoliter-scale Gyrolab® immunoassay platform for ligand-binding assays.


Learning Objectives:

  • Understand the advantages of the Gyrolab Bioaffy 4000 CD for extending assay sensitivity in pharmacokinetic and biomarker analysis.
  • Understand specific applications for MDBs and biomarker applications and the use of Gyrolab Bioaffy 4000 CD

This webinar was presented as part of Oxford Global Biomarkers Week on March 18, 2021.



Gyrolab Bioaffy 4000 CD: Extending Immunoassay Sensitivity in a Microfluidic Platform


John-Chappell-3-150x150John Chappell, Application & Service Director EMEA and Asia Pacific, Gyros Protein Technologies



Improving Existing Multidomain Biotherapeutic (MDB) PK Assay with Gyrolab 4000 CD


Carina Carter Photo 3


Carina Carter, Senior Scientist, EMD Serono






Development of a sensitive assay for detection of a serum biomarker using Gyrolab Bioaffy 4000 CDs.


Claire Seal_headshot



Claire Seal, Principal Scientist, F-Star Therapeutics







If you have problems to view the webinar please contact


Please register to view the webinar